BioSpace News Archive

Keros Therapeutics announces U.S. Food and Drug Administration (“FDA”) has cleared its investigational new drug application to conduct a Phase 2 clinical trial of KER-012 in combination with background therapy in patients with pulmonary arterial hypertension.

STRM.BIO today announced the appointment of Minnie Mildwoff, to its Board of Directors.

Cognizant (NASDAQ: CTSH) today announced an expansion of its relationship with Gilead Sciences (NASDAQ: GILD). Gilead is a leading biopharmaceutical company advancing innovative medicines to prevent and treat life-threatening diseases.

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), announced today that it will hold a conference call with PAH experts on Tuesday, July 25th at 10 a.m. EDT.

Medpace Holdings, Inc. announced financial results for the second quarter ended June 30, 2023.

Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2023 third quarter ended June 30, 2023, on Thursday, August 10, 2023, after the close of the stock market.

Cardiff Oncology, Inc. announced that on July 24, 2023, non-qualified stock option awards to purchase an aggregate of 50,016 shares of its common stock were granted to one new employee.

A presidential scholar from Pennsylvania is in Montreal this summer, applying her expertise to help a state-of-the-art lab at École Polytechnique de Montréal advance a breakthrough medical device that enables people with spinal cord injuries to move their limbs.

Further to press release dated May 3, 2023, the TSX Venture Exchange (“TSX-V”) requested Solarvest (TSXV: SVS) (or “the Company”) to provide a detailed analysis, subject to review and acceptance, to meet Tier 2 Continued Listing Requirements (“CLR”) by July 20, 2023.

Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, announced the publication of its Phase 3 CARES 310 study results in The Lancet.